Yuefeng Du

Dr. Yuefeng Du


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
BGBing Guan
Bing Guan
KWKaijie Wu
Kaijie Wu
JZJin Zeng
Jin Zeng
SXShan Xu
Shan Xu
LMLijun Mu
Lijun Mu
YDYuefeng Du
Yuefeng Du
Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer

1 September 2020 in Experimental Cell Research
Verified
Journal Article
Open access
JTJuanhua Tian
Juanhua Tian
HZHaibao Zhang
Haibao Zhang
LMLijun Mu
Lijun Mu
MWMeiyu Wang
Meiyu Wang
XLXudong Li
Xudong Li
YDYuefeng Du
Yuefeng Du
Altered expression of microRNA (miRNA) is associated with the occurrence and metastasis of various tumors. We previously found that miR-218 inhibits tumor angiogenesis through the RICTOR/VEGFA axis in prostate cancer (PCa). In this study, we determined that miR-218 also had a negative effect on cell growth, migration, and invasion ability in PCa. Our data showed that miR-218 bound to the Grb2-associated binding protein 2 (GAB2) 3'-UTR region and inhibited GAB2 expression. As a novel downstream target of miR-218, GAB2 has been reported to be involved in the occurrence and development of various human tumors, but its role in the progression and metastasis of PCa has not been addressed. We demonstrated for the first time that the expression of GAB2 in the PCa cell lines was increased, while knocking down GAB2 significantly inhibited cell growth, metastatic ability and EMT process in PCa. In addition, the recovery of GAB2 could reverse the changes in the biological function of PCa cells caused by the ectopic expression of miR-218. Mechanistically, miR-218-mediated GAB2 transcriptional suppression significantly inhibited the activity of the PI3K/AKT/GSK-3β pathway, whose abnormal activation was found to be related to the malignant progression of PCa. Taken together, our findings suggest that the miR-218/GAB2 axis may become a novel prognostic indicator and potential therapeutic target in PCa.

1 June 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
BGBing Guan
Bing Guan
LMLijun Mu
Lijun Mu
LZLinlin Zhang
Linlin Zhang
KWKe Wang
Ke Wang
JTJuanhua Tian
Juanhua Tian
YDYuefeng Du
Yuefeng Du
MicroRNA (miRNA) is a class of non‑coding single‑stranded RNA, able to regulate tumor‑associated genes via binding the 3'‑UTR of the target gene mRNA. Previous publications have demonstrated that miRNA‑218 (miR‑218) acts as a tumor‑suppressive miRNA in various types of human cancer, including prostate cancer (PCa). However, the role of miR‑218 in regulating PCa cell stemness and epithelial‑mesenchymal transition remains unknown and requires further research. In the present study, it is demonstrated that miR‑218 was downregulated in 2 PCa cell lines and could suppress cell migration, EMT and the exhibition of cancer stem cell‑like properties. The expression of GLI family zinc finger 1 (Gli1) was inhibited by miR‑218 overexpression, suggesting miR‑218‑suppression of Gli1 as a potential mechanism for the tumor‑suppressive effect of miR‑218. Overall, the results indicate that miR‑218 served a critical role in the inhibition of PCa development. This may provide new insight for elucidating the mechanisms of PCa oncogenesis and suggests that miR‑218 may be a novel therapeutic target for PCa.

8 September 2020 in Oncology Reports
Verified
Journal Article
Open access
PDF file
LMLijun Mu
Lijun Mu
BGBing Guan
Bing Guan
JTJuanhua Tian
Juanhua Tian
XLXiang Li
Xiang Li
QLQingzhi Long
Qingzhi Long
YDYuefeng Du
Yuefeng Du
Renal cell carcinoma (RCC) is one of the most common malignant cancers in the adult urinary system worldwide. Tumor angiogenesis is a critical process during cancer progression, as it modulates carcinogenesis and metastasis. In recent years, microRNA‑218 (miR‑218) has been confirmed to play a crucial role in tumor suppression. However, the role of miR‑218 in RCC angiogenesis remains unclear. In the present study, it was found that the expression of miR‑218 was decreased in RCC tumor tissues and cell lines as detected by real‑time PCR analysis. Tube formation assays and migration assays also confirmed that miR‑218 inhibited the interaction between RCC cells and vascular endothelial cells by suppressing proangiogenic factor vascular endothelial growth factor A (VEGFA) in RCC cells. miR‑218 also repressed the subcutaneous tumorigenesis of RCC cells in nude mice, and the corneal angiogenesis in rabbit eyes. The underlying molecular mechanism was elucidated; miR‑218 targets GRB2‑associated binding protein 2 (GAB2), thereby inhibiting the PI3K/AKT/mTOR/VEGFA pathway. These results provide new insights into the mechanism of RCC carcinogenesis and progression, suggesting that miRNA‑218 may be a therapeutic target for the treatment of RCC.

7 August 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
XQXiang-Rui Qiao
Xiang-Rui Qiao
XZXinwei Zhang
Xinwei Zhang
LMLijun Mu
Lijun Mu
JTJuanhua Tian
Juanhua Tian
YDYuefeng Du
Yuefeng Du
The development of prostate cancer is complicated and involves a number of tumor‑associated gene expression level abnormalities. Gene chip technology is a high‑throughput method that can detect gene expression levels in different tissues and cells on a large scale. In the present study, gene chip technology was used to screen differentially expressed genes in PC‑3 human prostate cancer cells following GRB‑associated binding protein 2 (GAB2) gene knockdown, and the corresponding biological information was analyzed to investigate the role of GAB2 in prostate cancer. The PC‑3 human prostate cancer cell GAB2 gene was knocked out and gene chip hybridization and bioinformatics methods were used to analyze the classical pathway and predict upstream regulatory molecules, disease and function associations and genetic interaction networks. According to the screening conditions |fold change|>1 and P<0.05, 1,242 differential genes were screened; 665 genes were upregulated, and 577 genes were downregulated. Ingenuity Pathway Analysis software demonstrated that GAB2 regulates pathways, such as the superpathway of cholesterol biosynthesis and p53 signaling in cells, and serves a role in diseases and functions such as ‘non‑melanoma solid tumors’, ‘viral infections’ and ‘morbidity or mortality’. In the occurrence and development of prostate cancer, factors such as the activation of genes involved in the proliferative cycle, abnormalities in metabolism‑associated enzyme gene activities and viral infection play key roles. The present study provides novel research directions and therapeutic targets for prostate cancer.

17 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BCBohong Chen
Bohong Chen
LGLi Guo
Li Guo
LWLihui Wang
Lihui Wang
PWPeiqiang Wu
Peiqiang Wu
XZXinyu Zheng
Xinyu Zheng
YDYuefeng Du
Yuefeng Du
Metastasis is the major cause of treatment failure in patients with prostate adenocarcinoma (PRAD). Diverse programmed cell death (PCD) patterns play an important role in tumor metastasis and hold promise as predictive indicators for PRAD metastasis. Using the LASSO Cox regression method, we developed PCD score (PCDS) based on differentially expressed genes (DEGs) associated with PCD. Clinical correlation, external validation, functional enrichment analysis, mutation landscape analysis, tumor immune environment analysis, and immunotherapy analysis were conducted. The role of Prostaglandin D2 Synthase (PTGDS) in PRAD was examined through in vitro experiments, single-cell, and Mendelian randomization (MR) analysis. PCDS is elevated in patients with higher Gleason scores, higher T stage, biochemical recurrence (BCR), and higher prostate-specific antigen (PSA) levels. Individuals with higher PCDS are prone to metastasis, metastasis after BCR, BCR, and castration resistance. Moreover, PRAD patients with low PCDS responded positively to immunotherapy. Random forest analysis and Mendelian randomization analysis identified PTGDS as the top gene associated with PRAD metastasis and in vitro experiments revealed that PTGDS was considerably downregulated in PRAD cells against normal prostate cells. Furthermore, the overexpression of PTGDS was found to suppress the migration, invasion, proliferationof DU145 and LNCaP cells. To sum up, PCDS may be a useful biomarker for forecasting the possibility of metastasis, recurrence, castration resistance, and the efficacy of immunotherapy in PRAD patients. Additionally, PTGDS was identified as a viable therapeutic target for the management of PRAD.